Elixhauser Comorbidity Measure and Charlson Comorbidity Index in Predicting the Death of Spanish Inpatients with Diabetes and Invasive Pneumococcal Disease.

Publication date: Jul 11, 2025

Invasive pneumococcal disease (IPD) is a serious infection caused by the bacterium Streptococcus pneumoniae (pneumococcus) that can produce a wide spectrum of clinical manifestations. The aim of this study was to analyze the comorbidity factors that influenced the mortality in patients with diabetes (D) according to IPD. A retrospective study to analyze patients with D and IPD was carried out. Based on the discharge reports from the Spanish Minimum Basic Data Set (MBDS) from 1997 to 2022, the Elixhauser Comorbidity Index (ECI) and the Charlson Comorbidity Index (CCI) were calculated to predict in-hospital mortality (IHM) in Spain. A total of 12,994,304 patients with D were included, and 84,601 cases of IPD were identified. The average age for men was 70. 23 years and for women 73. 94 years. In all years, ECI and CCI were larger for type 2 D than for type 1 D, with men having a higher mean than women. An association was found between risk factors ECI, age, type 1 D, COVID-19, IPD (OR = 1. 31; 95% CI: 1. 29-1. 35; p < 0. 001); CCI, age, type 1 D, COVID-19, IPD (OR = 1. 45; 95% CI: 1. 42-1. 49; p < 0. 001), and increased mortality. The IHM increased steadily with the number of comorbidities and index scores from 1997 to 2022. D remains a relevant cause of hospitalization in Spain. Comorbidities reflected a great impact on patients with D and IPD, which would mean a higher risk of mortality. Predicting mortality events and length of stay by comparing indices showed that CCI outperforms ECI in predicting inpatient death after IPD.

Open Access PDF

Concepts Keywords
Death comorbidity index
Diabetes diabetes
Microorganisms invasive pneumococcal disease
Spanish retrospective study
Spain

Semantics

Type Source Name
disease MESH Comorbidity
disease MESH Death
disease MESH Pneumococcal Disease
disease MESH infection
disease MESH COVID-19
disease MESH Respiratory Diseases
disease MESH chronic diseases
disease MESH complications
disease IDO pathogen
disease MESH morbidity
disease MESH asthma
pathway KEGG Asthma
disease MESH lung diseases
disease IDO immunosuppression
disease MESH liver diseases
disease MESH lifestyle
disease IDO intervention
disease MESH Influenza
disease IDO history
disease IDO disposition
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH cancer
disease MESH weight loss
disease MESH paralysis
disease MESH neurological disorders
disease MESH Hypertension
disease MESH Cardiac Arrhythmias
disease MESH COPD
disease MESH Congestive Heart Failure
disease MESH Renal Failure
disease MESH Drug Abuse
disease MESH AIDS

Original Article

(Visited 2 times, 1 visits today)